start-ver=1.4
cd-journal=joma
no-vol=102-B
cd-vols=
no-issue=8
article-no=
start-page=1088
end-page=1094
dt-received=
dt-revised=
dt-accepted=
dt-pub-year=2020
dt-pub=20200731
dt-online=
en-article=
kn-article=
en-subject=
kn-subject=
en-title=
kn-title=The role of radiotherapy in the treatment of superficial soft-tissue sarcomas
en-subtitle=
kn-subtitle=
en-abstract=
kn-abstract=Aims</br>
The existing clinical guidelines do not describe a clear indication for adjuvant radiotherapy (RT) in the treatment of superficial soft tissue sarcomas (STSs). We aimed to determine the efficacy of adjuvant RT for superficial STSs.</br>
Methods</br>
We retrospectively studied 304 patients with superficial STS of the limbs and trunk who underwent surgical resection at a tertiary sarcoma centre. The efficacy of RT was investigated according to the tumour size and grade: group 1, ? 5 cm, low grade; group 2, ? 5cm, high grade; group 3, > 5 cm, low grade; group 4, > 5 cm, high grade.</br>
Results</br>
The five- and ten-year local recurrence-free survival (LRFS) for all patients was 88% and 81%, respectively. While the efficacy of adjuvant RT was not proven in local control of all patients (five-year LRFS; RT+, 90% versus RT-, 83%; p = 0.074), the LRFS was significantly improved by adjuvant RT in group 2 (five-year LRFS; RT+, 96% versus RT-, 82%; p = 0.019), and group 4 (five-year LRFS; RT+, 87% versus RT-, 73%; p = 0.027). In groups 2 and 4, adjuvant RT significantly reduced the LR risk if the resection margin was clear but less than 5 mm; the LR rate was 7% with adjuvant RT compared with 26% with surgery alone (p = 0.003). There was no statistical relationship with the use of adjuvant RT and survival in every group.</br>
Conclusion</br>
Adjuvant RT reduces the risk of local recurrence in patients with superficial high-grade STS regardless of tumour size, especially when resection margin is less than 5 mm.
en-copyright=
kn-copyright=

en-aut-name=FujiwaraTomohiro
en-aut-sei=Fujiwara
en-aut-mei=Tomohiro
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=1
ORCID=

en-aut-name=TsudaYusuke
en-aut-sei=Tsuda
en-aut-mei=Yusuke
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=2
ORCID=

en-aut-name=Le NailLouis-Rom?e
en-aut-sei=Le Nail
en-aut-mei=Louis-Rom?e
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=3
ORCID=

en-aut-name=EvansScott
en-aut-sei=Evans
en-aut-mei=Scott
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=4
ORCID=

en-aut-name=GregoryJonathan
en-aut-sei=Gregory
en-aut-mei=Jonathan
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=5
ORCID=

en-aut-name=TillmanRoger
en-aut-sei=Tillman
en-aut-mei=Roger
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=6
ORCID=

en-aut-name=AbuduAdesegun
en-aut-sei=Abudu
en-aut-mei=Adesegun
kn-aut-name=
kn-aut-sei=
kn-aut-mei=
aut-affil-num=7
ORCID=

affil-num=1
en-affil=Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
kn-affil=

affil-num=2
en-affil=The Royal Orthopaedic Hospital NHS Foundation Trust
kn-affil=

affil-num=3
en-affil=The Royal Orthopaedic Hospital NHS Foundation Trust
kn-affil=

affil-num=4
en-affil=The Royal Orthopaedic Hospital NHS Foundation Trust
kn-affil=

affil-num=5
en-affil=The Royal Orthopaedic Hospital NHS Foundation Trust
kn-affil=

affil-num=6
en-affil=The Royal Orthopaedic Hospital NHS Foundation Trust
kn-affil=

affil-num=7
en-affil=The Royal Orthopaedic Hospital NHS Foundation Trust
kn-affil=
END